Business Case

Characterized Hemophilia GTx Infusion center networks and developed processes to track and validate center readiness, informing commercial strategy and planning at a large pharmaceutical company

LSC worked with a large pharmaceutical company actively developing a gene therapy for hemophilia but seeking to understand how to identify and target patients for treatment. LSC broke the leading global launch countries into regions and evaluated the infrastructure of care in these regions, specifically looking at the density and competency of infusion and referral centers to “type” the local infrastructure of care. Aligning infrastructure types allowed LSC, with our client, to identify type-specific challenges, potential solutions, and support strategies, ultimately increasing the expected number of patients ~40% and ensuring patients have robust availability of care, regardless of where they live.